KT 009

Drug Profile

KT 009

Alternative Names: KT009; Recombinant growth factor - Kunovus Technologies

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kunovus Technologies
  • Class Growth factors
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Intervertebral disc degeneration

Most Recent Events

  • 26 May 2017 KT 009 is available for licensing as of 26 May 2017.
  • 26 May 2017 Preclinical trials in Intervertebral disc degeneration before May 2017 (Bio-Link Australia pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top